Needle Free Injections Market

Needle Free Injections Market by Product Type (Fillable and Prefilled), Technology (Jet-Based, Spring-Based, and Others), Usability (Reusable and Disposable), Application (Vaccine, Insulin, Dermatology, and Others), End-User (Hospitals, Clinics, Homecare Settings, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the increasing incidence of chronic diseases, rising number of needle stick injuries, growing focus on vaccination programs and rising technology innovation across the globe.

The needle-free injection systems market was valued at USD 12.49 billion in 2023, growing at a CAGR of 14.16% during the forecast period from 2024 to 2030 to reach USD 27.65 billion by 2030. The needle-free injection market is poised for substantial growth, driven by a confluence of critical factors. The increasing incidence of chronic diseases such as diabetes, rheumatoid arthritis, and chronic pain necessitates frequent and often lifelong drug administration, making less invasive, more comfortable delivery methods highly desirable for improving patient adherence and quality of life. Concurrently, the rising number of needle stick injuries among healthcare workers highlights the urgent need for safer alternatives to traditional needles. Needle-free systems eliminate the risk of needle stick injuries, thereby enhancing occupational safety and reducing associated healthcare costs. Additionally, the growing focus on vaccination programs, underscored by global efforts to combat diseases, underscores the importance of efficient, rapid, and pain-free vaccine administration. Needle-free technologies facilitate mass immunization by offering a painless alternative that can increase public compliance and streamline the vaccination process. Furthermore, rapid technological innovations in the medical field are continually improving the effectiveness, precision, and user-friendliness of needle-free injection systems, making them more accessible and reliable during the forecast period from 2024 to 2030.

Needle-Free Injections Market Dynamics:

According to the recent data provided by the Centre for Disease Control and Prevention (2024), approximately 385,000 needle sticks and other sharps-related injuries occurred annually among hospital-based healthcare personnel. Similar injuries took place in other healthcare settings, including nursing homes, clinics, emergency care services, and private homes. These injuries were primarily linked to the occupational transmission of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV), as well as over 20 other pathogens. Thus, the increased cases of needle stick injuries highlight the critical need for safer alternatives for the administration of drugs and therapeutics. Needle-free injection systems can eliminate these risks, enhancing the safety of healthcare workers and reducing the associated healthcare costs and liabilities thereby boosting the overall market of needle-free injections across the globe.

Additionally, according to the recent data provided by Global Burden of Disease (2023), by 2050, nearly one billion people are projected to have osteoarthritis, with the most common areas affected being the knees and hips. Specifically, osteoarthritis of the knee is expected to increase by 74.9%, osteoarthritis of the hand by 48.6%, osteoarthritis of the hip by 78.6%, and osteoarthritis in other areas, such as the elbow and shoulder, by 95.1%. Arthritis, including osteoarthritis, often requires regular administration of medications such as corticosteroids, hyaluronic acid, or disease-modifying antirheumatic drugs (DMARDs). Needle-free injection systems such as Needle-Free Jet Injectors which use high-pressure jets to propel medications subcutaneously or intra-articularly, Intra-articular Sprays which can deliver medications directly into the joint space, offering a non-invasive option for managing arthritis-related symptoms, Microneedle Patches which are used for delivering anti-inflammatory medications directly into joints affected by arthritis, these patches use microscopic needles to painlessly administer drugs through the skin's surface are further propelling the overall market due to rise in cases of chronic pain.

Furthermore, according to the recent update provided by the International Diabetes Federation, in 2021, approximately 537 million adults aged 20-79 were living with diabetes. This number was projected to rise to 643 million by 2030 and 783 million by 2045. Diabetes management often requires frequent insulin administration, traditionally done through needle-based injections. Thus, needle-free injection systems offer a less invasive, pain-free alternative that can improve patient comfort and compliance thereby boosting the overall market of needle-free injections. For example, in October 2023, NuGen Medical Devices Inc., a company known for needle-free drug delivery, announced the official launch of its InsuJet™ devices in Canada. InsuJet is a needle-free injection system, which is designed to improve the lives of millions of people suffering from diabetes.

However, high-pressure jet injectors, used in some needle-free systems, can potentially cause tissue damage or irritation, and needle-free injection systems may not penetrate deeply enough to reach certain tissues or deliver medications effectively in all clinical scenarios may hinder the future market of needle-free injections during the forecasted period.

Needle-Free Injections Market Segment Analysis:

Needle Free Injections Market by Product Type (Fillable and Prefilled), Technology (Jet-Based, Spring-Based, and Others), Usability (Reusable and Disposable), Application (Vaccine, Insulin, Dermatology, and Others), End-User (Hospitals, Clinics, Homecare Settings, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the application segment of the needle-free injections market, the vaccine category is projected to hold a considerable market share in 2023. The global market for needle-free injections is significantly bolstered by the increasing demand and adoption of needle-free injection systems in vaccination programs worldwide. Vaccinations are crucial for preventing infectious diseases and are administered to individuals of all ages, from infants to the elderly, as well as in mass vaccination campaigns during outbreaks or pandemics.

Additionally, in mass vaccination campaigns, such as those conducted during global health emergencies, needle-free injection systems streamline the vaccination process. They enable rapid, efficient administration of vaccines to large populations, helping healthcare providers meet high demand and achieve widespread immunization coverage quickly and safely. According to the recent data provided by the World Health Organization (2024), in 2023, the proportion of children receiving a first dose of measles vaccine was 83%. 

Additionally, successful clinical trials on needle-free vaccination play a pivotal role in boosting the market for needle-free injections by validating their safety, efficacy, and superiority. For example, in May 2023, Micron Biomedical announced positive results from its first clinical trial of microarray injection-free vaccine delivery in children, demonstrating efficacy in measles and rubella vaccination. Thus, successful clinical trials provide scientific evidence of the safety and effectiveness of needle-free injection systems across various therapeutic areas and patient populations. Positive trial outcomes, showing comparable or improved outcomes compared to needles, build confidence among healthcare providers, regulators, and patients thereby boosting the market of the segment.

Furthermore, regulatory agencies worldwide are increasingly recognizing the safety, efficacy, and benefits of needle-free injection systems for vaccine delivery. This regulatory support facilitates market expansion by encouraging healthcare providers and organizations to integrate these technologies into their immunization strategies.

Therefore, owing to the above-mentioned factors, the vaccination category is expected to generate considerable revenue thereby pushing the overall growth of the global needle-free injections market during the forecast period.

North America is expected to dominate the Overall Needle-Free Injections Market:

North America is expected to account for the highest proportion of the needle free injections market in 2023, out of all regions North America is expected to dominate the overall needle free injections market during the forecast period. The growing prevalence of chronic pain, diabetes, and others in the region is anticipated to boost the demand for needle free injections during the forecasted period across the region. Additionally, recent product approvals, launches, and clinical trials by the key market players actively manufacturing needle free injections will also contribute to the market growth. Moreover, increasing government initiatives further propels the market of needle free injections by creating awareness programs, and other activities across the region.

According to the recent data provided by the Centre for Disease Control and Prevention (2023), in 2021, an estimated 20.9% of U.S. adults, totaling 51.6 million persons, experienced chronic pain, while 6.9%, or 17.1 million persons, experienced high-impact chronic pain—defined as pain significantly restricting daily activities. Chronic pain conditions such as arthritis, fibromyalgia, and lower back pain often require frequent administration of pain-relieving medications. Needle-free injection systems offer a less invasive alternative to traditional needles, potentially improving patient compliance with treatment regimens that require repeated injections thereby boosting the overall market of needle free injection across the region.

Additionally, as per the recent data provided by the IDF Diabetes Atlas, in 2021, approximately the total number of diabetes cases in North America and the Caribbean was 51 million. Diabetes management often requires frequent insulin injections, especially for patients with type 1 diabetes or those with advanced type 2 diabetes. Needle-free insulin injection systems offer a less invasive alternative to traditional needles, potentially improving patient compliance with insulin therapy regimens that require multiple daily injections thereby escalating the market of needle free injection across the region.

Additionally, successful clinical trials in the United States provide scientific evidence of the effectiveness of needle-free injection systems across various medical conditions and patient demographics. Positive trial outcomes, showing comparable or improved treatment outcomes compared to traditional needles, instill confidence among healthcare providers, regulators, and patients. For example, in March 2024, PassPort Technologies, Inc. announced the positive interim phase-1 results of Zolmitriptan Transdermal Microporation System for the Treatment of Acute Migraine. Zolmitriptan PassPort® is a needle-free combination system consisting of a microporation device and zolmitriptan patch, which was applied on the individual's upper arm to deliver zolmitriptan into the systemic circulation via micropores painlessly created in the skin.

Therefore, the above-mentioned factors are expected to bolster the growth of the needle free injections market in North America during the forecast period.

Needle-Free Injections Market Key Players:

Some of the key market players operating in the Needle Free Injections market include IntegriMedical LLC, INJEX Pharma GmbH, PharmaJet Corporation, CrossJect, European Pharma Group BV, National Medical Products Inc., Akra DermaJet, Meika Medical Co, Basco India., Mystic Pharmaceuticals Inc, Technologies Médicales Internationales (MIT Canada) Inc., INOVIO Pharmaceuticals, MADA MEDICAL PRODUCTS INC., Portal Instruments, D'Antonio Consultants International, Inc., Micron Biomedical, NuGen Medical, Orlance, Inc., Bryn Pharma, LLC., PassPort Technologies, Inc., NovaXS, and others.

Recent Developmental Activities in Needle-Free Injections Market:

• In July 2024, Seattle-based biotech Orlance, Inc. received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop and improve RNA vaccine formulations using its needle-free MACH-1™ platform.
• In May 2024, the Serum Institute of India (SII), the world's largest vaccine manufacturer, announced a strategic investment in IntegriMedical, acquiring a 20% stake in the company, to advance Needle-Free Injection System technology.
• In November 2022, NovaXS unveiled a new prototype of needle-free injection therapy smart medical device.
• In August 2022, PharmaJet and their partner Zydus Cadila announced the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world’s first Plasmid DNA Vaccine for COVID-19. The vaccine- ZyCoV-D is exclusively administered by the deployment of the PharmaJet Tropis® Needle-free Injection System.
• In May 2022, Gerresheimer AG expanded its portfolio with highly innovative platform technologies for drug delivery. The company, known for healthcare and beauty solutions, as well as drug delivery systems for pharma, biotech, and cosmetics, announced an investment in US-based Portal Instruments, a developer of next-generation needle-free drug delivery technology.

Key Takeaways from the Needle-Free Injections Market Report Study

• Needle free injections product providers
• Research organizations and consulting companies 
• Needle free injections -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in needle free injections 
• Various end-users who want to know more about the needle free injections market and the latest technological developments in the needle free injections market.  

Target Audience who can be benefited from this Needle-Free Injections Market Report Study

• Needle-free injection systems products providers
• Research organizations and consulting companies
• Needle-free injection systems -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in needle-free injections market
• Various End-Users who want to know more about the needle-free injections market and the latest technological developments in the needle-free injections market

Frequently Asked Questions for Needle-Free Injections Market:

1. What are needle free injections?

Needle-free injections are medical devices that deliver medications through the skin without the use of traditional needles. They utilize various technologies such as high-pressure jets, microneedles, or patches to administer drugs, vaccines, or other substances directly into the body, offering a less invasive and often more comfortable alternative to needle-based injections.

2. What is the market for needle free injections?

The needle-free injection systems market was valued at USD 12.49 billion in 2023, growing at a CAGR of 14.16% during the forecast period from 2024 to 2030 to reach USD 27.65 billion by 2030.

3. What are the drivers for the needle free injections market?

The needle-free injection market is poised for substantial growth, driven by a confluence of critical factors. The increasing incidence of chronic diseases such as diabetes, rheumatoid arthritis, and chronic pain necessitates frequent and often lifelong drug administration, making less invasive, more comfortable delivery methods highly desirable for improving patient adherence and quality of life. Concurrently, the rising number of needle stick injuries among healthcare workers highlights the urgent need for safer alternatives to traditional needles. Needle-free systems eliminate the risk of needle stick injuries, thereby enhancing occupational safety and reducing associated healthcare costs. Additionally, the growing focus on vaccination programs, underscored by global efforts to combat diseases, underscores the importance of efficient, rapid, and pain-free vaccine administration. Needle-free technologies facilitate mass immunization by offering a painless alternative that can increase public compliance and streamline the vaccination process. Furthermore, rapid technological innovations in the medical field are continually improving the effectiveness, precision, and user-friendliness of needle-free injection systems, making them more accessible and reliable during the forecast period from 2024 to 2030.

4. Who are the key players operating in the needle free injections market?

Some of the key market players operating in the Needle Free Injections market include IntegriMedical LLC, INJEX Pharma GmbH, PharmaJet Corporation, CrossJect, European Pharma Group BV, National Medical Products Inc., Akra DermaJet, Meika Medical Co, Basco India., Mystic Pharmaceuticals Inc, Technologies Médicales Internationales (MIT Canada) Inc., INOVIO Pharmaceuticals, MADA MEDICAL PRODUCTS INC., Portal Instruments, D'Antonio Consultants International, Inc., Micron Biomedical, NuGen Medical, Orlance, Inc., Bryn Pharma, LLC., PassPort Technologies, Inc., NovaXS, and others.

5. Which region has the highest share in the needle free injections market?

North America is expected to account for the highest proportion of the needle free injections market in 2023, out of all regions North America is expected to dominate the overall needle free injections market during the forecast period. The growing prevalence of chronic pain, diabetes, and others in the region is anticipated to boost the demand for needle free injections during the forecasted period across the region. Additionally, recent product approvals, launches, and clinical trials by the key market players actively manufacturing needle free injections will also contribute to the market growth. Moreover, increasing government initiatives further propels the market of needle free injections by creating awareness programs, and other activities across the region.